Antibody-drug conjugate · developed by Immunome
IM-1340 is an antibody-drug conjugate, an antibody carrying a cytotoxic drug payload. It is studied in colorectal cancer, non-small cell lung cancer, small cell lung cancer and neuroendocrine neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07890246 | Phase 1 | Colorectal Cancer | Not yet recruiting | IMNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerNeuroendocrine NeoplasmNon-Small Cell Lung CancerSmall Cell Lung Cancer
Updated Nov 15, 2026. Something wrong or missing? Report it on the IMNM page.
See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNM catalysts and pipeline →